A Feasible Strategy of Fabricating Redox-Responsive Polymeric Salinomycin Small Molecule Prodrug Delivery for Liver Cancer Therapy.

Salinomycin (SM), a naturally occurring anti-tumour agent, is beneficial in treating a broad range of cancerous tumours. This is due to SM's limited aqueous solubility and poor bioavailability. Polyethylene glycol was conjugated to SM via a disulfide bond to alleviate the limitations of the previous technique. Small micelles (diameter ~ 63.5 nm) with excellent drug loading efficacy (~ 16.7%) and reduction and pH dual-sensitivity may be synthesized using this formulation, which self-assembles into micelles (SM-SS-Ms) in the aqueous solutions. A liver HepG2 cancer cell and its mice model xenograft were slandered methods in cell and animal investigations to demonstrate that SM-SS-Ms formulation could substantially extend the blood circulation and encourage tumour tissue accumulation. Antitumor effectiveness is achieved by SM-SS-Ms being targeted for accumulation in cancer cells, where they are quickly released into the intracellular microenvironment, which is acidic and glutathione-rich. [ABSTRACT FROM AUTHOR]